RE: Weekly forecasts20 Feb 2023 20:38
Mani - Happy now? Cash is good for at least 12months!
"The directors have prepared financial forecasts to estimate the likely cash requirements of the Group over the period to 30 September 2023, given its stage of development and lack of recurring revenues. In preparing these financial forecasts, the directors have made certain assumptions with regards to the timing and amount of future expenditure over which they have control. The directors have taken a prudent view in preparing these forecasts and will not commit to expenditure which the Group can't meet out of existing resources.
The Group's available resources at the date of this report are sufficient to cover the Group's committed activities of interacting with platform and other investigator-led studies, designing a broad-spectrum antiviral clinical trial, engaging with pharmaceutical companies regarding collaboration/licensing opportunities for that broad indication and, if required, engaging with providers of any other type of funding (details of these activities, current operating expense levels to 30 June 2022 and working capital at 30 June 2022 can be found in the Operating and Financial Reviews). Regardless of the outcome of these activities, which are uncertain, the Group's available resources are sufficient to cover existing committed costs and the costs of these activities until at least 30 September 2023.
After due consideration of these forecasts and current cash resources, the directors consider that the Group has adequate financial resources to continue in operational existence for the foreseeable future (being a period of at least twelve months from the date of this report) and, for this reason, the financial statements have been prepared on a going concern basis."